The company's EPS is expected to grow 7.4% this year, crushing the industry average, which calls for EPS growth of 4.8%. Impressive Asset Utilization Ratio Growth investors often overlook asset utilization ratio, also known as sales-to-total-assets (S/TA) ratio, but it is an important feature of a real growth stock. This metric shows how efficiently a firm is utilizing its assets to generate sales. Right now, Haemonetics has an S/TA ratio of 0.56, which means that the company gets $0.56 in sales for each dollar in assets. Comparing this to the industry average of 0.53, it can be said that the company is more efficient. While the level of efficiency in generating sales matters a lot, so does the sales growth of a company. And Haemonetics looks attractive from a sales growth perspective as well. The company's sales are expected to grow 9.2% this year versus the industry average of 3.7%.